Navigation Links
DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of,Improved Glycemic Control and Significant Reductions of,LDL-Cholesterol and C-Reactive Protein

Top Line Data for the Treatment of Type 2 Diabetes Presented at the 67th Annual Scientific Sessions of American Diabetes Association

SAN FRANCISCO, June 25, 2007 /PRNewswire/ -- DiObex, Inc., a privately-held biopharmaceutical company focused on the development of therapeutics to treat metabolic diseases, today announced the presentation of top line data of its phase 2a study of DIO-902, a first-in-category Cortisol Synthesis Inhibitor for the treatment of type 2 diabetes.

Results of the two week placebo-controlled, dose-ranging study demonstrated that in patients treated with DIO-902 there was a trend toward improved glycemic control as measured by HbA1c, fructosamine and fasting blood glucose, as well as significant dose-dependent reductions in total and LDL- cholesterol. Mean levels of C-reactive protein (a marker of cardiovascular inflammation) were also significantly reduced in a dose-dependent fashion. Besides glycemic control, the additional benefits provided by DIO-902 may allow type 2 diabetes patients to manage their disease with fewer medications.

The data was presented at the 67th Annual Scientific Sessions of the American Diabetes Association (ADA) in Chicago, IL by Sherwin Schwartz, MD, lead investigator from the Diabetes and Glandular Disease Clinic of San Antonio, Texas. In his oral presentation, Dr. Schwartz detailed the results of the recently completed multi-center, randomized, placebo-controlled trial of DIO-902 in patients with type 2 diabetes.

"DIO-902 was well tolerated and we saw early signals of improvements in glycemic control," said Dr. Schwartz. "In addition, DIO-902 also showed early indications of potential to reduce the risk of heart disease through the significant reduction of LDL-cholesterol by as much as 46 percent at the highest dose studied. The prospect of a single therapeutic which has the potential to address multiple co-morbidities is very exciting."<
'"/>




Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
11. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
Post Your Comments:
(Date:12/24/2014)... Dec. 23, 2014 Tianyin Pharmaceutical Co., ... specializes in patented biopharmaceutical, modernized traditional Chinese medicine ... today announced that the Company achieved the Public ... Practice (GMP) certificate of TPI,s Qionglai Facility (QLF) ... The public notice period is a significant procedure ...
(Date:12/22/2014)... NxStage Medical, Inc. (NASDAQ: NXTM ... announced today that the U.S. Food and Drug ... perform hemodialysis overnight while the patient is at ... System One is the first and only hemodialysis ... Home nocturnal hemodialysis is an ...
(Date:12/22/2014)... , Dec. 22, 2014  ConvaTec, a privately-held ... Moraviec has been appointed Interim Chief Executive Officer of ... Moraviec succeeds Ken Berger .  "The Board of ... in leading ConvaTec over the past three years," said ... of Directors.  "We are confident that the company is ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... Oct. 18, 2011 Octapharma USA ... over the next few months, including AABB,s 64th Annual ... 25 and National Hemophilia Foundation,s (NHF) 63rd Annual Meeting ... In December, Octapharma USA will also participate in the ...
... Oct. 18, 2011 For thousands of nurses, lab technicians, ... of shopping for the latest in scrub fashions that are ... on the success of the 10 original stores that launched ... to open in Tampa, Orlando and Miami FL; Rochester and ...
Cached Medicine Technology:Octapharma USA to Participate in Important Medical Meetings at AABB, NHF, ASHP and ASH 2Octapharma USA to Participate in Important Medical Meetings at AABB, NHF, ASHP and ASH 3Octapharma USA to Participate in Important Medical Meetings at AABB, NHF, ASHP and ASH 4An RX for Busy Healthcare Professionals 2An RX for Busy Healthcare Professionals 3
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a comprehensive ... and marketing of a series of induction heating equipment. ... series of induction brazing equipments . , According ... brazing refers to the joining of two or ... The manager says that there are fundamental differences in ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
(Date:12/25/2014)... When head lice hits a home or school, parents and ... of it while keeping it from taking over the house ... solution right in their neighborhood: Lice Troopers . Expanding ... spectrum head lice screening and treatment services to families and ... Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. , The ...
(Date:12/25/2014)... early stage breast cancer patients who undergo chemotherapy and/or ... eventually develop leukemia as a result of their treatment, ... a review of more than 20,000 breast cancer cases ... the risk for developing treatment-related leukemia, though low, is ... frequency of bone marrow cancers such as leukemia is ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... , , , HATBORO, Pa., ... a leading technology provider of enterprise mobility solutions for the healthcare ... panel discussion as part of Mobile Monday Mid-Atlantic, Monday September 21, ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090618/NE35135LOGO ) ...
... , , , ... NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic ... financing with institutional and other accredited investors, including members of ... half of the offering. Gross proceeds of approximately $2.9 million ...
... HLTH Corporation (Nasdaq: HLTH ) today announced that ... segment to affiliates of Aurora Capital Group, a Los Angeles based ... the fourth quarter and is subject to customary closing conditions, including ... Act. , , The purchase price of ...
... Sept. 18 NBTY, Inc. (NYSE: NTY ) ( ... today announced that it will web cast presentations by Harvey Kamil, President ... , , Mr. Kamil,s presentation at the ... 2009 will be web cast at 4:30 PM Eastern Time that day. ...
... , , CLEVELAND, Sept. ... 45-minute seminar that highlights the critical need for long-term care insurance ... available. It will be held at multiple times in 4 Ohio ... , , *(PHOTO 72dpi: Send2Press.com/mediaboom/09-0910-3in4ltc_72dpi.jpg) ...
... , , , ... www.maxhealthcare.in ) and Perot Systems Corporation (NYSE: PER ... which Perot Systems will provide IT outsourcing (ITO) and electronic health records ... in the Indian healthcare industry as well as the company,s first India-based ...
Cached Medicine News:Health News:InfoLogix to Present 'Mobile in the Enterprise: Keeping up with User Demand While Containing Costs' at Mobile Monday Panel in Philadelphia 2Health News:InfoLogix to Present 'Mobile in the Enterprise: Keeping up with User Demand While Containing Costs' at Mobile Monday Panel in Philadelphia 3Health News:NewCardio Completes $2.9 Million Private Placement 2Health News:NewCardio Completes $2.9 Million Private Placement 3Health News:NewCardio Completes $2.9 Million Private Placement 4Health News:HLTH Corporation Announces Agreement to Sell Porex Unit to Aurora Capital Group for $142 Million 2Health News:HLTH Corporation Announces Agreement to Sell Porex Unit to Aurora Capital Group for $142 Million 3Health News:NBTY to Web Cast Presentations at UBS Global Life Sciences Conference and Canaccord Adams Healthy Living Conference 2Health News:NBTY to Web Cast Presentations at UBS Global Life Sciences Conference and Canaccord Adams Healthy Living Conference 3Health News:Long Term Care Seminars in Dayton, Cleveland, Cincinnati, and Columbus -- Free to Public 2Health News:Long Term Care Seminars in Dayton, Cleveland, Cincinnati, and Columbus -- Free to Public 3Health News:Max Healthcare of India Selects Perot Systems for Over Rs. 90 Crores ($18 Million) 10-year IT Services and Electronic Health Records Implementation 2Health News:Max Healthcare of India Selects Perot Systems for Over Rs. 90 Crores ($18 Million) 10-year IT Services and Electronic Health Records Implementation 3Health News:Max Healthcare of India Selects Perot Systems for Over Rs. 90 Crores ($18 Million) 10-year IT Services and Electronic Health Records Implementation 4Health News:Max Healthcare of India Selects Perot Systems for Over Rs. 90 Crores ($18 Million) 10-year IT Services and Electronic Health Records Implementation 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: